Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (81-90 of 436) with videos related to

Pageof 44
Sort By:
The New England Journal of Medicine|April 19, 2008
Pharmaceutical promotion to physicians and First Amendment rightsAaron S Kesselheim, Jerry Avorn
Health Affairs (Project Hope)|October 11, 2012
The Food and Drug Administration has the legal basis to restrict promotion of flawed comparative effectiveness researchAaron S Kesselheim, Jerry Avorn
JAMA Internal Medicine|February 7, 2017
Applying Academic Detailing and Process Change to Promote Choosing WiselyMichael Fralick, Aaron Kesselheim, Jerry Avorn
The New England Journal of Medicine|September 3, 2005
Statins and the risk of colorectal cancerSoko Setoguchi, Jerry Avorn, Sebastian Schneeweiss
The New England Journal of Medicine|September 20, 2018
The FDA Amendments Act of 2007 - Assessing Its Effects a Decade LaterJerry Avorn, Aaron Kesselheim, Ameet Sarpatwari
JAMA Network Open|April 19, 2022
Use of Extrapolation in New Drug Approvals by the US Food and Drug AdministrationDaniel Feldman, Jerry Avorn, Aaron S Kesselheim
Journal of Clinical Epidemiology|January 30, 2008
Pharmacoepidemiology and "in silico" drug evaluation: is there common ground?Til Stürmer, Kenneth J Rothman, Jerry Avorn
American Heart Journal|April 29, 2008
The economic consequences of non-evidence-based clopidogrel useNiteesh K Choudhry, Raisa Levin, Jerry Avorn
Archives of Internal Medicine|January 25, 2006
Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effectsWinfried Rief, Jerry Avorn, Arthur J Barsky
The New England Journal of Medicine|September 3, 2015
Forbidden and Permitted Statements about Medications--Loosening the RulesJerry Avorn, Ameet Sarpatwari, Aaron S Kesselheim
Pageof 44

Showing results (81-90 of 436) with videos related to

Sort By:
Pageof 44
The New England Journal of Medicine|April 19, 2008
Pharmaceutical promotion to physicians and First Amendment rightsAaron S Kesselheim, Jerry Avorn
Health Affairs (Project Hope)|October 11, 2012
The Food and Drug Administration has the legal basis to restrict promotion of flawed comparative effectiveness researchAaron S Kesselheim, Jerry Avorn
JAMA Internal Medicine|February 7, 2017
Applying Academic Detailing and Process Change to Promote Choosing WiselyMichael Fralick, Aaron Kesselheim, Jerry Avorn
The New England Journal of Medicine|September 3, 2005
Statins and the risk of colorectal cancerSoko Setoguchi, Jerry Avorn, Sebastian Schneeweiss
The New England Journal of Medicine|September 20, 2018
The FDA Amendments Act of 2007 - Assessing Its Effects a Decade LaterJerry Avorn, Aaron Kesselheim, Ameet Sarpatwari
JAMA Network Open|April 19, 2022
Use of Extrapolation in New Drug Approvals by the US Food and Drug AdministrationDaniel Feldman, Jerry Avorn, Aaron S Kesselheim
Journal of Clinical Epidemiology|January 30, 2008
Pharmacoepidemiology and "in silico" drug evaluation: is there common ground?Til Stürmer, Kenneth J Rothman, Jerry Avorn
American Heart Journal|April 29, 2008
The economic consequences of non-evidence-based clopidogrel useNiteesh K Choudhry, Raisa Levin, Jerry Avorn
Archives of Internal Medicine|January 25, 2006
Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effectsWinfried Rief, Jerry Avorn, Arthur J Barsky
The New England Journal of Medicine|September 3, 2015
Forbidden and Permitted Statements about Medications--Loosening the RulesJerry Avorn, Ameet Sarpatwari, Aaron S Kesselheim
Pageof 44